Acadia Pharmaceuticals, Inc. operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Acadia Pharmaceuticals with three other companies in this sector in UNITED STATES : Ironwood Pharmaceuticals Incorporation (2020 sales of $389.52 million of which 100% was human therapeutics.), Alnylam Pharmaceuticals, Inc. ($492.85 million of which 100% was Biopharmaceutical), and Pacira Biosciences Inc ($429.65 million of which 100% was discovery, development, manufacture, mar).

Sales Analysis. During the first quarter of 2021, sales at Acadia Pharmaceuticals totalled $106.55 million. This is an increase of 18.3% from the $90.07 million in sales at the company during the first quarter of 2020. During the previous 20 quarters, sales at Acadia Pharmaceuticals have increased compared with the same quarter in the previous year. Acadia Pharmaceuticals reported sales of $441.76 million for the year ending December of 2020. This represents an increase of 30.3% versus 2019, when the company's sales were $339.08 million. Sales at Acadia Pharmaceuticals have increased during each of the previous five years (and since 2015, sales have increased a total of 724,089%).